View Profile

Dr, Vinod Kumar Gurjar

Associate professor · Faculty of Pharmacy Parul University

https://researchid.co/vgpharma
@paruluniversity.ac.in
19Scopus Publications
144Google Scholar Citations
6Google Scholar h-index
4Google Scholar i10-index

Research Interests

Phytochemistry

Biography

Dr. Vinod Kumar Gurjar completed his B. Pharm. in 2003 from VNS Institute of Pharmacy, under Rajiv Gandhi Technical University, Bhopal, Madhya Pradesh and M. Pharm. (Pharmaceutical chemistry) in 2008 from Department of Pharmaceutical Sciences Dr. Hari Singh Gour University (A Central University), Sagar Madhya Pradesh. Dr. Vinod pursued PhD from Department of Pharmaceutical Sciences Guru Ghasidas Vishwavidyalaya (A central University), Bilaspur Chhattisgarh. He is currently working as associate professor in School of Pharmacy, Parul University Vadodara, Gujarat, India. His research interest areas are in the field of synthesis and evaluation of heterocyclic compound, computer aided drug design. He has published 5 research articles and one review paper in peer reviewed journals. He wrote 9 international book chapter. He is credited with patents granted and published. He has presented numbers of papers in national and international conferences. He is a life member of APTI, APP and SPER. pr

Recent Scopus Publications

  1. Azoles (triazole and imidazole) scaffolds in anticancer drug design
    Nitrogen Heterocycles in Cancer Therapy, 2025
  2. Reinstating the expression and activation of caspase-8 and caspase-10 in cancer therapy
    Caspases as Molecular Targets for Cancer Therapy, 2024
  3. Medicinal Plants in Controlling and Treatment of Diseases Caused by Viral Hemorrhagic Septicemia Virus (VHSV)
    Reference Series in Phytochemistry, 2024
  4. Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase inhibitors
    Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy, 2024
  5. Rearranged during transfection (RET) inhibitors
    Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy, 2024

Links